Topical chemotherapy patch for early oral cancer (Stage 0) to support a phase 3 trial
Official title: Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
Funded at Privo Technologies, LLC · NIH-11361063 · Data updated 2026-11-12
A new topical patch delivering chemotherapy directly to the tumor is being tested to help people with very early oral cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Privo Technologies, LLC NIH-funded |
| Lab location | 1 site (Peabody, United States) |
| Project start | June 14, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,170,285 |
| NIH project number | 5R44CA281020-09 |
| Project ID | NIH-11361063 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with stage 0 oral cancer or carcinoma in situ who may be eligible for the topical PRV111 patch in a future trial.
✕Less likely to help
Patients with more advanced disease or contraindications to chemotherapy may not benefit from this early-stage topical approach.
What this research studies
This project aims to enable a Phase 3 clinical trial of a novel topical treatment (PRV111) for carcinoma in situ of the oral cavity, aiming to reduce long-term side effects and preserve function. The patch delivers cisplatin-loaded nanoparticles through the mucous membrane directly to the tumor area. By supporting registration and trial readiness, the study seeks to move promising therapy toward broader patient access. If successful, patients could benefit from a treatment option that minimizes surgical morbidity and preserves quality of life.
Why it matters
Potential benefit: If successful, patients with early oral cancer may receive an effective, less invasive treatment that reduces long-term disabilities and costs.
How similar studies have gone: Previous localized chemotherapy approaches have shown potential in preserving function, but this exact topical patch is novel for this indication.
Where this research is happening
-
Privo Technologies, LLC
Peabody, United States Active
Researchers
- Principal investigator: Goldberg, Manijeh N — Privo Technologies, LLC
- Study coordinator: Goldberg, Manijeh N
Related research
Other NIH-funded projects on the same topics.
-
A Nanotechnology Patch for Early-Stage Oral Cancer
This project supports a late-stage clinical trial for a new topical patch designed to treat early-stage oral cancer.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Mobile platform using AI to screen for oral cancer in low-resource communities
A low-cost, AI-powered mobile tool helps frontline healthcare workers screen for oral cancer and triage patients in communities with limited access to specialists.
-
Endosomal signaling and cancer pain control in oral cancer
A study to understand how signals inside nerve cells and supportive cells contribute to pain in people with oral cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.